Adagene Inc. (ADAG)
1.52
-0.03 (-2.25%)
At close: Mar 31, 2025, 2:23 PM
1.61
5.90%
After-hours: Mar 31, 2025, 07:00 PM EDT
-2.25% (1D)
| Bid | 1.39 |
| Market Cap | 57.29M |
| Revenue (ttm) | 700.29K |
| Net Income (ttm) | -27.34M |
| EPS (ttm) | -0.74 |
| PE Ratio (ttm) | -2.05 |
| Forward PE | -2.41 |
| Analyst | Strong Buy |
| Ask | 1.86 |
| Volume | 11,844 |
| Avg. Volume (20D) | 73,033 |
| Open | 1.50 |
| Previous Close | 1.55 |
| Day's Range | 1.50 - 1.59 |
| 52-Week Range | 1.39 - 3.58 |
| Beta | 0.50 |
About ADAG
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical tr...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 9, 2021
Employees 138
Stock Exchange NASDAQ
Ticker Symbol ADAG
Website https://www.adagene.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ADAG stock is "Strong Buy." The 12-month stock price forecast is $8, which is an increase of 426.32% from the latest price.
Stock Forecasts7 months ago
+8.86%
Adagene shares are trading higher after the compan...
Unlock content with
Pro Subscription
